Share Cancellation
HAI summary · Not investment advice
Hanmi Pharmaceutical decided to retire 85,316 common shares of previously acquired treasury stock on November 2, 2026.
Cancellation amount
KRW 28.3 billion
Based on the book value of the shares to be retired
Key facts
- Acquisition method
- Treasury shares already acquired
- Cancellation date
- Nov 2, 2026May change following consultation with relevant authorities
- Board resolution date
- Oct 27, 2026
Commentary
AI commentary · Not investment advice
What happened
Hanmi Pharmaceutical decided to cancel 85,316 common shares of treasury stock it had already acquired. The planned cancellation amount is KRW 28.3 billion, and the scheduled cancellation date is 2026.11.02. The board approved the decision on 2026.10.27, and the filing was received the same day.
In the company's terms
Relative to the company, the cancellation amounts to 0.6% of market capitalization. The shares to be cancelled are previously acquired treasury shares, not newly purchased ones. The total number of issued common shares is currently disclosed as 12,810,991.
What changes for shareholders
For shareholders, the date to note is the scheduled cancellation date of 2026.11.02. Once the cancellation is carried out, the number of issued shares will decrease by the 85,316 common shares being cancelled.
Show Korean comments
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist